Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial.
David A Palma, Eitan Prisman, Eric Berthelet, Eric Tran, Sarah Hamilton, Jonn Wu, Antoine Eskander, Kevin Higgins, Irene Karam, Ian Poon, Zain Husain, Danny Enepekides, Michael Hier, Keith Richardson, Alex Mlynarek, Stephanie Johnson-Obaseki, Marc Gaudet, Andrew Bayley, Samuel Dowthwaite, James E Jackson, Marcin Dzienis, John O'Neil, Shamir Chandarana, Robyn Banerjee, Robert Hart, Jeffson Chung, Todd Tenenholtz, Hien Le, John Yoo, Adrian Mendez, Eric Winquist, Sara Kuruvilla, Paul Stewart, Andrew Warner, Sylvia Mitchell, Jeff Chen, Christina Parker, Keith Kwan, Julie Theurer, Houda Bahig, Apostolos Christopoulos, Lucas C Mendez, Jinka Sathya, J Alex Hammond, Nancy Read, Varagur Venkatesan, Kevin Fung, Anthony C Nichols
Eur J Cancer 220 115343
摘要
摘要
BACKGROUND: The optimal treatment de-escalation approach for HPV-related oropharyngeal squamous cell carcinomas (OPSCC) is unknown. The objective was to assess two de-escalation approaches: primary radiotherapy (RT) vs. transoral surgical (TOS). PATIENTS AND METHODS: Patients with T1-T2 N0-2 HPV-related OPSCC were randomly assigned to primary RT (60 Gy with concurrent weekly cisplatin in node-positive) vs. TOS + neck dissection (ND) (and adjuvant reduced-dose RT depending on pathology). The primary endpoint was 2-year OS (hypothesized to be 94 % in each arm, compared to 84 %). Secondary endpoints included comparisons of survival and quality of life between arms. The trial was stopped early due to two treatment related deaths in the surgical arm. RESULTS: Sixty-one patients were randomized (n = 30 in RT arm and n = 31 in TOS+ND arm), with a median age of 62 years (IQR: 57-68). The majority were male (n = 51) and never-smokers (n = 31). Median follow-up was 3.7 years (IQR: 3.1-4.5 years). In the RT arm, the primary endpoint for acceptability was met (p = 0.008), and two-year OS was 100 % (95 % confidence interval [CI]: 100-100 %). In the TOS+ND arm, the primary endpoint was not met (p = 0.296) and two-year OS was 90 % (95 % CI: 71-97 %), significantly worse than the RT arm (p = 0.041). Two-year progression-free survival (PFS) were 100 % (95 % CI: 100-100 %) vs. 86 % (95 % CI: 67-95 %) respectively (p = 0.012). Mean (± SD) 2-year MDADI total scores were 89 ± 13 vs. 83 ± 11, respectively (p = 0.11), and grade 2-5 toxicity rates were similar (n = 21 vs. n = 24 respectively, p = 0.51), with no additional grade 5 events. CONCLUSION: For treatment de-escalation, a primary RT approach achieved excellent oncologic and functional outcomes and should be tested in phase III de-escalation trials. TRIAL REGISTRATION: Clinicaltrials.gov NCT03210103.
KM 提取结果
0 个 Figure · 0 个 KM 面板